Related references
Note: Only part of the references are listed.Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial
Corinne Faivre-Finn et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Heather A. Wakelee et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
Jonathan Spicer et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer
Jeffrey D. Bradley et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.
Sacha Rothschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
Catherine A. Shu et al.
LANCET ONCOLOGY (2020)
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Mariano Provencio et al.
LANCET ONCOLOGY (2020)
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
Martin Fruh et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)
Alessandra L. Curioni-Fontecedro et al.
BRITISH JOURNAL OF CANCER (2019)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors
Christoph Poettgen et al.
BMC CANCER (2015)
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)
Wilfried Ernst Erich Eberhardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-A multicenter phase-II trial (CISTAXOL)
Wilfried Ernst Erich Eberhardt et al.
LUNG CANCER (2013)
A Phase 3 Study of Induction Treatment With Concurrent Chemoradiotherapy Versus Chemotherapy Before Surgery in Patients With Pathologically Confirmed N2 Stage IIIA Nonsmall Cell Lung Cancer (WJTOG9903)
Nobuyuki Katakami et al.
CANCER (2012)
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
Kathy S. Albain et al.
LANCET (2009)
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Effect of preoperative chemoradiation in addition to preoperative chemotherapy:: a randomised trial in stage III non-small-cell lung cancer
Michael Thomas et al.
LANCET ONCOLOGY (2008)
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer
Jan P. van Meerbeeck et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer
RJ Stephens et al.
LUNG CANCER (2005)
Mediastinal lymph node clearance after docetaxel-cisplatin Neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer:: A multicenter phase II trial
DC Betticher et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); Final report of RTOG 89-01
DW Johnstone et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Share Paper
